Category: Dermatology

Categories : Dermatology PaediatricsTags : Leave a comment

Do Babies Really Need Sunscreen? The Risks of Overuse and Underuse

On By ModernMedia
Photo by Marissa Daeger on Unsplash

When it comes to protecting babies from the sun, many parents wonder if sunscreen is safe and necessary. The truth is, experts advise against using sunscreen on infants under six months old as their skin is thinner and more sensitive, leading to greater absorption of chemicals and a higher risk of irritation and rashes.

Babies under six months have a higher surface-area-to-body-weight ratio, which increases their exposure to sunscreen chemicals. Some chemical ingredients, like oxybenzone, may cause allergic reactions or disrupt hormones. Sunscreen can also impede a baby’s ability to sweat and regulate their body temperature. 

Instead, the best protection for young babies is to keep them out of direct sunlight, dress them in lightweight, long-sleeved clothing, and use hats and shade as natural barriers. 

For babies over six months, a gentle, broad-spectrum baby sunscreen with at least SPF 30 can be safely applied. However, using sunscreen should complement, not replace, other sun safety measures, which are vital – especially in our sunny South African climate! 

Karen Van Rensburg, spokesperson for Sanosan, explains, “Parents often struggle with knowing how much sunscreen to use on their babies. It’s important to understand that while sunscreen is a helpful tool, relying solely on it, especially for very young infants, can be risky. Using physical barriers like shade and protective clothing alongside sunscreen provides the safest approach to sun care for babies.”

To keep babies safe, parents should:

  • Avoid sun exposure during peak hours (10 a.m. to 4 p.m.)
  • Use shade and protective clothing as the first defence.
  • For babies over six months, reapply a suitable sunscreen on a regular basis to maintain protection, especially after going in the water, after drying off or after sweating. 
  • Your baby should not stay in the sun too long even with sunscreen because every sunburn damages the skin and is a serious risk to their health. 

This balanced approach highlights that cautious sunscreen use combined with physical protection methods is key to keeping baby skin healthy and safe from sun damage.

Sanosan Baby Sun Cream SPF 50+ is a top-tier sunscreen designed specifically for delicate baby skin including broad range of UVA+UVB protection SPF 50+. With its pleasant texture, this cream absorbs quickly for easy application and delivers 24 hours of nourishing care, making it suitable for babies, children, and adults alike. With its gentle formula, this sun cream helps maintain skin hydration while protecting against sun damage, allowing for worry-free outdoor playtime. Plus, its microplastic-free, and safe for our oceans!

Categories : DermatologyTags : Leave a comment

Phase 3 Success for Rocatinlimab in Moderate-to-severe Eczema

On By ModernMedia

Two global trials show durable improvements in skin clearance, itch, and quality of life by targeting OX40 immune receptor

Source: Unsplash CC0

An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, has reported results from the first phase 3 clinical trials of rocatinlimab, a novel treatment for moderate-to-severe atopic dermatitis (eczema). The landmark findings from the ROCKET-IGNITE and ROCKET-HORIZON studies were published in The Lancet. 

Eczema affects hundreds of millions of people worldwide and is notoriously difficult to treat due to its complex and chronic inflammatory pathways. Current biologics focus on blocking “allergy” cytokines but fail to address the memory T cells that sustain disease activity. Rocatinlimab is the first antibody to selectively block the OX40 receptor on effector and memory T cells, rebalancing the immune system and altering the long-term course of disease. 

Across the two global, double-blind, placebo-controlled randomised phase 3 clinical trials, nearly 1,500 patients were followed for 24 weeks, and rocatinlimab showed robust and lasting benefits. Patients receiving the treatment were three times more likely to achieve significant improvement in eczema severity, as measured by EASI and vIGA-AD scores, compared to those on placebo. Improvements continued beyond week 24, suggesting that the benefits strengthen over time. The therapy also led to meaningful reductions in itch, pain, and sleep disturbances, enhancing overall quality of life. Importantly, rocatinlimab was well tolerated, with adverse events comparable to placebo, and demonstrated high selectivity by reducing only the OX40R+ CD4+ T cells responsible for eczema’s persistence, without off-target effects. 

“These findings represent a major advance for patients living with eczema, who often face years of uncontrolled symptoms and few effective options,” said physician scientist, Dr. Guttman-Yassky, lead author of the study. “By targeting memory T cells through OX40, rocatinlimab not only clears the skin and relieves itch, but continues to improve patients’ lives over time with a strong safety profile. This is the first phase 3 proof that rebalancing these immune cells can transform how we treat atopic dermatitis.” 

The results establish OX40 as a validated treatment target in eczema and position rocatinlimab as a potential first-in-class therapy. Patients from the phase 3 trials are now being followed in the ROCKET-ASCEND extension study, which will track outcomes for up to two years. Additional research will explore its role in paediatric patients, in combination with other therapies, and in direct comparisons to existing systemic treatments. 

Source: The Mount Sinai Hospital

Categories : Cancer DermatologyTags :

Controlling Inflammation from Sunburn May Prevent Skin Cancer

On By ModernMedia
Photo by Rfstudio on Pexels

In a new study published in Nature Communications, researchers at the University of Chicago have discovered how prolonged exposure to ultraviolet (UV) radiation can trigger inflammation in skin cells through degradation of a key protein called YTHDF2. This protein acts as a gatekeeper in preventing normal skin cells from becoming cancerous. The finding reveals that YTHDF2 plays a crucial role in regulating RNA metabolism to keep cells in a healthy state and opens the door to developing potential new approaches to skin cancer prevention and treatment.

Uncontrolled inflammation triggers skin cancer

Each year, nearly 5.4 million people in the United States are diagnosed with skin cancer, with more than 90% of cases attributed to excessive UV exposure. UV rays can damage DNA and cause oxidative stress and inflammation in skin cells — leading to redness, pain and blistering, commonly known as sunburn.

“We’re interested in understanding how inflammation caused by UV exposure contributes to the development of skin cancer,” said Yu-Ying He, PhD, Professor of Medicine in the Section of Dermatology at the University of Chicago.

RNA or ribonucleic acid is an essential molecule that helps convert genetic information into proteins. A special class known as non-coding RNAs regulates gene expression without producing proteins. These molecules typically function in either the nucleus, where a cell’s DNA is stored or the cytoplasm, where most cellular activity occurs.

Low levels of YTHDF2 turn normal skin cells cancerous

He’s laboratory studies how environmental stressors, such as UV radiation or arsenic in drinking water, affect molecular pathways and damage cellular systems, leading to cancer. Through screening various enzymes, the researchers found that UV exposure causes a marked decrease in levels of YTHDF2, a “reader” protein that specifically binds to RNA sequences marked with a chemical tag known as N6-methyladenosine (m6A).

“When we removed YTHDF2 from skin cells, we saw that UV-triggered inflammation was much worse,” He said. “This suggests that the YTHDF2 protein plays a key role in suppressing inflammatory responses.”

Although inflammation is essential for fighting off infections, it also plays a major role in causing life-threatening diseases, including cancer. However, the molecular mechanisms that regulate this response, especially after UV damage, are not well understood.

YTHDF2 in regulation of non-coding RNA interactions

Using multi-omics analysis and additional cellular assays, the research team found that YTHDF2 binds to a specific non-coding RNA known as U6, which is modified by m6A and classified as a small nuclear RNA (snRNA). Under UV stress, cancer cells showed increased levels of U6 snRNA, and these modified RNAs were found to interact with toll-like receptor 3 (TLR3), an immune sensor known to activate inflammatory pathways linked to cancer.

Surprisingly, these interactions occurred within endosomes, where cellular compartments are typically involved in recycling materials, not where U6 snRNA is usually located.

“We spent a lot of time figuring out how these non-coding RNAs get to the endosome, since that’s not where they usually reside,” He explained. “For the first time, we showed that a protein called SDT2 transports U6 into the endosome, and YTHDF2 travels with it.”

Once both YTHDF2 and m6A-modified U6 RNA arrive at the endosome, YTHDF2 blocks the RNA from activating TLR3. However, when YTHDF2 is absent – such as after UV damage, the RNA freely binds to TLR3, triggering harmful inflammation.

“Our study uncovers a new layer of biological regulation, a surveillance system through YTHDF2 that helps protect the body from excessive inflammation and inflammatory damage,” He said.

The findings could open the door to new strategies for preventing or treating UV-induced skin cancer by targeting the RNA-protein interactions that regulate inflammation.

Source: University of Chicago Medicine

The study, “YTHDF2 regulates self non-coding RNA metabolism to control inflammation and tumorigenesis,” was supported by grants from the National Institutes of Health, the University of Chicago Medicine Comprehensive Cancer Center, the ChicAgo Center for Health and EnvironmenT (CACHET), and the University of Chicago Friends of Dermatology Endowment Fund.

Categories : DermatologyTags :

Dark Clinics, Real Risks: The Hidden Dangers of Illegal Hair Transplants in South Africa

On By ModernMedia

Infections, scarring, and even death are lurking behind slick ads

Photo by Towfiqu barbhuiya

In a tiny back room, with outdated instruments and no doctor in sight, a “hair transplant” begins. Weeks later, patients arrive at legitimate clinics with infections that won’t heal, patchy or missing hair, and permanent scarring – some even with necrotic tissue. This isn’t just happening abroad in countries like Turkey and Pakistan; South Africa has its own growing underground hair transplant industry: the so-called “dark clinics”.

These clinics operate everywhere. In mobile setups, or purely online. Many are run by unlicensed practitioners who are far from registered doctors. Many staff aren’t even legally allowed to work in the country. Regulation is patchy. Enforcement is almost impossible given that they operate for a few weeks and then disappear. And the people who pay the price? Everyday men and women desperate to fix hair loss but who are unable to afford quality and safety.

“Most people have no idea what they’re walking into when visiting one of these clinics,” says Dr Kashmal Kalan, Medical Director at Alvi Armani South Africa. “We see patients quite often who come to us after unsatisfactory or botched procedures. And yes, some cases are life-threatening. These clinics operate with no oversight, no hygiene protocols, and zero accountability.”

The harm isn’t just cosmetic. Rogue clinics routinely cut corners. Non-medical staff perform invasive procedures. Sterile instruments? Often non-existent. Infection control? Minimal. Follow-up care? None. Patients are sometimes rushed into procedures without proper consent, unaware of realistic outcomes or potential complications. What starts as a “cheap deal” can quickly spiral into months of medical interventions, emotional trauma, revision surgeries, and financial strain.

Dr Kalan explains the lure: “These clinics play on insecurity, urgency, and the desire for fast results. Social media and online payments make it easy for unqualified operators to reach people. Most patients don’t ask the hard questions. They only learn the truth when it’s too late. One patient described it as the worst mistake of his life – a promise of transformation that turned into months of pain, scarring, and regret.”

Hard truths: Red flags to watch out for

A legitimate clinic is open, accountable, and transparent. Dark clinics thrive on secrecy, pressure tactics, and the promise of cheap shortcuts. Patients must ask:

  1. Is the surgeon fully qualified, licensed, and registered in South Africa?
    • Do they have a valid Health Professions Council of South Africa (HPCSA) license? Are they legally allowed to practice in South Africa?
  2. Which technique will be used and why?
    • Follicular Unit Extraction (FUE), Follicular Unit Transplantation (FUT), Direct Hair Implantation (DHI) – what’s suitable for your hair type and hair-loss pattern?
  3. How many grafts will I need, and what can I realistically expect?
    • Outcomes depend on donor area, hair quality, and pattern of hair loss.
  4. What are the risks, and how are they managed?
    • Infection control, emergency protocols, and complication plans must be clear.
  5. What aftercare is in place?
    • Who monitors healing? How frequent are follow-ups? Can you contact someone if there’s a problem?
  6. Can I see genuine before-and-after photos?
    • Photos must be comparable, real, and relevant to your hair type.
  7. Is the clinic accredited and registered with the relevant health authority?
    • The facility must be sterile, clean, and transparent.

Regulators such as the HPCSA and The South African Health Products Regulatory Authority (SAHPRA) try to police illegal clinics, but dark clinics operate under the radar – changing locations, staff, and online presence frequently, creating a perfect storm of vulnerability.

The only safe route: choose a qualified, certified, and accountable practitioner. Look for transparency, credentials, consultations, and thorough aftercare. Ask questions.

Dr Kalan warns: “Do your homework. Don’t chase the cheapest option. Cheap shortcuts in cosmetic procedures are rarely worth it. Your hair can be restored safely, but the damage from a dark clinic? That can scar you for life.”

Categories : Dermatology New Compounds and TreatmentsTags :

Hydrogen Sulphide Could Be the Answer to Treating Nail Infections

On By ModernMedia

Scientists at Bath and King’s College London have discovered that a common chemical could be used to develop a new treatment for difficult-to-treat nail infections.

Paronychia. Source: Wikimedia Commons CC0

Hydrogen sulphide, the volcanic gas that smells of rotten eggs, could be used in a new treatment for tricky nail infections that acts faster but with fewer side effects, according to scientists at the University of Bath and King’s College London (KCL).

Nail infections are mostly caused by fungi and occasionally by bacteria. They are very common, affecting between 4-10% of the global population, rising to nearly half those aged 70 or over.

These infections can lead to complications, particularly in vulnerable groups such as diabetics and the elderly, but are notoriously difficult to treat.

Current treatments include oral antifungals taken in pill form, and topical treatments which are applied directly to the nail.

Oral antifungals take around 2-4 months to act and are reasonably effective, but they carry risks of side effects, especially in patients with other medical conditions.

Treatments applied directly to the nail are safer, but they often take much longer to work, sometimes taking even years to work, and they frequently relapse or fail.

This is largely because it’s very difficult to get the drug to penetrate through the nail to where the infection resides.

Even the most effective topical treatments have relatively low cure rates, so there is a clear need for new therapeutic approaches that are safe, effective, and capable of reaching microbes embedded deep within the nail.

A team from the University of Bath and King’s College London has now found that hydrogen sulphide (H₂S), a small, naturally occurring gas, could be developed into a promising new treatment.

Previous work has shown that it penetrates the nail plate far more efficiently than existing topical drugs, and now the team has demonstrated that it has strong antimicrobial activity against a wide range of nail pathogens, including fungi that are resistant to common antifungal treatments.

In laboratory tests, the team used a chemical that breaks down to release the H₂S gas and found that it acts in a unique way, disrupting microbial energy production and triggering irreversible damage, ultimately killing the fungi.

The research is published in Scientific Reports.

Dr Albert Bolhuis, from the University of Bath’s Department of Life Sciences, said: “Thanks to its ability to efficiently reach the site of infection and its novel mode of action, we believe that a topically applied medicine containing hydrogen sulphide could become a highly effective new treatment for nail infections, which avoids the limitations of current therapies.

“Our research lays the foundation for a compelling alternative to existing treatments, with the potential to improve outcomes for patients suffering from persistent and drug-resistant fungal nail infections.”

Hydrogen sulphide is known for its pungent smell of rotten eggs, and has some toxicity, however researchers believe the amounts required are well below toxicity levels and the correct formulation will limit any unpleasant odours.

The research has so far only been done in vitro, but the team hopes to develop a treatment that could be used in patients in the next five years.

Professor Stuart Jones, Director of the Centre for Pharmaceutical Medicine Research at KCL said: “We are looking forward to translating these findings into an innovative topical product that can treat nail infection.”

Source: University of Bath

Categories : DermatologyTags :

When Hair Breaks Records: What Extraordinary Growth Reveals about Hair

On By ModernMedia

Science-backed insights and fascinating feats from the world of hair growth

Photo by Natasha Brazil on Unsplash

From a 2.26-metre Afro to hair strong enough to suspend a person mid-air, some of the world’s most jaw-dropping records remind us just how extraordinary human hair can be. While these feats may seem unbelievable, they highlight the biology behind hair’s strength, resilience, and growth potential.

“Exceptional hair growth is the result of discipline, not coincidence,” says Dr Kashmal Kalan, Medical Director at Alvi Armani South Africa. “A healthy scalp and uninterrupted growth cycles form the foundation for strong, resilient hair.”

The Biology Behind Every Strand

Hair grows in three phases: anagen (growth), catagen (transition), and telogen (rest). The anagen phase – lasting anywhere from two to seven years – largely determines how long hair can grow before naturally shedding. People who achieve exceptional lengths often have extended anagen phases, allowing their hair to keep growing far beyond the average.

While genetics set the baseline, lifestyle and environment play a powerful role in influencing growth potential. Nutrition, hormones, stress levels, and scalp health all impact the length and quality of the anagen phase. “We can’t rewrite DNA,” notes Dr Kalan, “but we can influence how genes express themselves.”

Lifestyle Matters

Healthy hair begins long before the styling stage.

  • Nutrition: Diets rich in protein, healthy fats, and vitamins support follicle strength.
  • Stress: Elevated stress hormones can shorten the growth phase and trigger shedding.
  • Sleep: Proper rest gives follicles the recovery time they need.
  • Scalp care: Gentle exfoliation, oiling, and protective styling can improve circulation and reduce breakage.

Science over hype

Despite bold marketing promises, there are no “miracle” serums that can regrow hair overnight. “Anything claiming dramatic growth in weeks is a red flag,” says Dr Kalan. Scientifically supported treatments – such as platelet-rich plasma (PRP), mesotherapy, and exosome therapy – can optimise follicle function, strengthen roots, and support sustained, natural growth.

“Healthy hair growth is a process grounded in biology, not marketing,” adds Dr Kalan.

Regenerative Approaches for Natural, Lasting Results

At Alvi Armani South Africa, regenerative science is at the core of every treatment. Using advanced techniques such as Follicular Unit Extraction (FUE) alongside PRP and exosome therapy, the clinic works with the body’s own biology to restore growth naturally.

“Our goal is always natural, lasting outcomes – hair that feels and looks strong, resilient, and vibrant,” concludes Dr Kalan.

From strength and endurance to sheer volume and creativity, these hair-related world records showcase just how remarkable human hair can be.

  • Most golf tees in hair: Anya Bannasch (USA) set a 2024 record with 711 golf tees in her hair – almost double her original goal.
  • Longest time suspended by hair: Leila Noone, a circus artist, hung from a single knot of her hair for over 25 minutes beneath California’s redwoods in 2025.
  • Largest afro: Jessica Martinez from New York City is attempting to break the record with an afro measuring about 36 cm high and 51 cm wide, inspiring confidence in natural hair.
  • Largest ball of human hair: “Hoss”, made entirely from donated hair, continues to grow through global contributions and features in Ripley’s Believe It or Not! exhibitions.

These feats highlight the versatility, strength, and creative expression found in something as simple – and as complex – as human hair.

For more information, visit www.alviarmani.co.za.

Categories : Dermatology PaediatricsTags :

Decoding Baby Eczema and Reassurance for Parents

On By ModernMedia
Photo by William Fortunato

For many South African parents, few things are more stressful than watching their baby’s delicate skin flare up with redness, dryness, or tiny itchy patches. Baby eczema, also called atopic dermatitis, affects up to 1 in 5 children worldwide – and while it’s common, it can leave parents feeling worried and overwhelmed.

But the good news is, with the right skincare routine, baby eczema is manageable. And no, it doesn’t mean your little one will always struggle with sensitive skin.

“Parents are often surprised to learn that baby eczema is not a sign that they’re doing something wrong,” says Karen Van Rensburg, spokesperson for Sanosan South Africa. “It’s a common skin condition linked to an underdeveloped skin barrier, and the key is to protect and strengthen that barrier with gentle care.”

Baby eczema usually shows up between two and six months of age. It can appear on the face, behind the ears, on the arms, legs, or even the chest. The skin becomes dry, red, itchy and, in some cases, scaly.

“Triggers vary,” explains Van Rensburg. “It could be heat, dry air, soaps with harsh ingredients, or even certain fabrics. Understanding what sparks your baby’s flare-ups is an important step in managing the condition.”

So what can parents do at home? Here are some dermatologist-approved tips:

1. Keep baths short and sweet
Stick to lukewarm water and limit bath time to 5–10 minutes. Avoid bubble baths and fragranced soaps.

2. Moisturise immediately after bathing
Lock in hydration by applying a fragrance-free, gentle moisturiser while your baby’s skin is still slightly damp.

3. Choose your products wisely
Opt for creams specifically designed for sensitive baby skin. Look for formulas enriched with natural oils, chamomile, or panthenol – like those found in Sanosan’s baby skincare range.

4. Watch the wardrobe
Dress your baby in soft, breathable cotton and avoid scratchy fabrics like wool. Always wash new clothes before wearing.

5. Spot and soothe flare-ups early
At the first sign of redness or irritation, apply a gentle, protective cream to calm the skin.

6. Don’t overheat the room
Babies with eczema are often sensitive to heat. Keep the nursery cool and use a humidifier if the air feels very dry.

7. See a healthcare professional when needed
If the rash is severe, infected, or your baby seems very uncomfortable, always seek medical advice.

“Parents sometimes think stronger products will ‘fix’ eczema faster,” says Van Rensburg. “But baby skin is incredibly delicate. Harsh ingredients strip away natural oils and make things worse. Gentle, consistent care is far more effective in the long run.”

Baby eczema can feel daunting, but with the right care and patience, most little ones outgrow it as their skin barrier matures. In the meantime, gentle skincare, lots of cuddles, and a watchful eye on triggers can make the world of difference.

“Think of it as supporting your baby’s skin while it learns to protect itself,” Van Rensburg adds. “You’re not just treating eczema – you’re helping build a healthy foundation for life.”

Sanosan focuses on natural ingredients and gentle formulas for healthy skin. Using active ingredients specially tailored to your baby’s skin, natural milk protein is the central ingredient in Sanosan and is especially nourishing. More than 90 % of the ingredients are of natural origin such as organic olive oil, and the formulations are biodegradable.

Safety first: all products are clinically tested and are free from parabens, silicones, paraffins, SLS / SLES and phenoxyethanol. For more info visit sanosan.co.za

Categories : Dermatology Mental HealthTags :

A Hidden Risk Behind a Common Hair Loss Drug

On By ModernMedia
Photo by Brett Sayles on Unsplash

For over two decades, finasteride – a prescription drug taken by millions of men to treat hair loss – has carried troubling signals of deeper harm: depression, anxiety, and in some cases, suicide.

A new review by Prof Mayer Brezis of the Hebrew University of Jerusalem argues that the medical and regulatory community failed the public by repeatedly overlooking evidence of finasteride’s potentially psychiatric effects.

The review, published in The Journal of Clinical Psychiatry, compiles data from eight major studies conducted between 2017 and 2023, showing a consistent pattern: users of finasteride were significantly more likely to experience mood disorders and suicidal thoughts than those not taking the drug. Findings come from multiple countries and data systems, including the US FDA, as well as national health records in Sweden, Canada, and Israel.

“The evidence is no longer anecdotal,” said Prof. Brezis, professor emeritus of medicine and public health. “We now see consistent patterns across diverse populations. And the consequences may have been tragic.”

According to the paper, hundreds of thousands of people may have suffered from depression related to finasteride, and hundreds – possibly more – may have died by suicide. 

A Delayed Response, With a High Cost

While the FDA acknowledged depression as a potential side effect in 2011 and added suicidality in 2022, concerns had already been raised as early as 2002. Internal FDA documents from 2010, cited in Prof Brezis’ paper, reveal large portions blacked out as “confidential” – including estimates of how many users could have been affected.

By 2011, the FDA had recorded just 18 suicides linked to finasteride. Based on global usage, he argues, the number should have been ranged in the thousands. “It wasn’t just underreporting,” he wrote. “It was a systemic failure of pharmacovigilance.”

Unlike weight-loss or psychiatric medications, which receive intense post-marketing scrutiny, finasteride’s “cosmetic” status may have shielded it from investigation. Notably, none of the studies cited in Brezis’ review were initiated by Merck, the original manufacturer, or requested by regulators.

A Cosmetic Drug With Life-Altering Risks

Finasteride works by blocking the conversion of testosterone into dihydrotestosterone (DHT). In the process, it may also disrupt neurosteroids like allopregnanolone, which are linked to mood regulation in the brain. Animal studies show long-term effects on neuroinflammation and even structural changes in the hippocampus.

For some patients, the harm does not end when the drug is stopped. Reports of “post-finasteride syndrome” describe lingering symptoms – insomnia, panic attacks, cognitive dysfunction, and suicidal thoughts – that persist months or years after discontinuation.

Regulatory Gaps and Corporate Silence

The report is particularly critical of the FDA and Merck. Despite having access to millions of patient records, neither acted in time. Brezis suggests that industry silence was strategic, motivated by market pressures and legal liability -echoing past controversies like Merck’s handling of Vioxx.

“Nothing is more important to Organon than the safety of our medicines,” the company recently stated. Yet none of the safety studies cited were initiated by the manufacturer.

The FDA, meanwhile, took five years to respond to a citizen petition calling for a black-box warning. Its final decision was to add suicidal ideation to the label – but not as a formal warning.

What Now?

Brezis is calling for immediate changes in how drugs like finasteride are approved, monitored, and prescribed. His recommendations include:

  • Suspending marketing of the drug for cosmetic purposes until safety is re-established.
  • Rquiring mandatory post-approval studies with strict enforcement.
  • Systematically recording drug histories in suicide investigations.

For many patients, those reforms will come too late.

The paper, “Failing Public Health Again? Analytical Review of Depression and Suicidality from Finasteride” was published in The Journal of Clinical Psychiatry and is available here. 

Source: Hebrew University of Jerusalem

Categories : DermatologyTags :

The True Burden of Eczema Goes Beyond the Itch

On By ModernMedia

World Atopic Eczema Day 2025 calls for early intervention, better care, and greater awareness of the hidden toll of atopic dermatitis.

Photo By: Kaboompics.com

On 14 September, people around the world marked World Atopic Eczema Day 2025 under the theme: “Our Skin, Our Journey.” This year’s campaign highlights the lifelong nature of atopic eczema, also known as atopic dermatitis (AD), a disease that usually begins in infancy and can progress to food allergies, asthma and allergic rhinitis.1

“Atopic eczema is more than a skin condition, it is driven by a dysregulated immune system and may have long-term physical and psychological impacts, and creates significant costs for families and healthcare systems,” says Dr Dwayne Koot, pharmacologist and Medical Advisor at Sanofi South Africa.

A disease that begins early

Atopic eczema is one of the most common chronic inflammatory skin diseases, affecting up to 20 percent of children globally.1 It often appears early in life. Around 45 percent of children with atopic eczema develop symptoms before six months of age, 60 percent before one year, and up to 85 percent before five years.1 For many, atopic eczema is the first step in what researchers call the “atopic march,” the progression from skin barrier dysfunction to food allergies and respiratory diseases.2

Studies show that infants with atopic eczema are six times more likely to develop egg allergy and eleven times more likely to develop peanut allergy than infants without atopic eczema.3 By later childhood, as many as 40 percent of children with atopic eczema develop food allergies.2 The condition does not stop there. School-age children with early, persistent atopic eczema face higher risks of developing asthma and allergic rhinitis.4

Beyond the skin

Atopic eczema is now recognised as a systemic disease linked to type 2 inflammation.1 The hallmark symptoms are itching, dry and inflamed skin, recurrent infections and disturbed sleep. These symptoms are not only uncomfortable but also disruptive to daily life.2,5

“Children may struggle at school due to fatigue, and parents often miss work or are unproductive due to sleepless nights, medical appointments or caring for their sick child,” says Dr Koot. “Because atopic eczema is so visible, children often face stigma. Studies show they are more likely to experience anxiety, depression and bullying. Up to one in three children with atopic eczema have anxiety or depression, compared with far fewer children without the disease.”

The economic impact is significant. In South Africa, while direct healthcare costs are relatively low (0,2 percent of healthcare spend), the total burden may be substantial when adding the much higher indirect costs and quality-of-life impacts.6

Why early intervention matters

While research is ongoing, one study found that daily use of emollients from birth to protect the skin barrier may lower the risk of eczema by half for high-risk infants, with no safety concerns.7

Additional research shows that the skin barrier is key in both atopic eczema and food allergies and protecting it early in life may help prevent these conditions.3 While allergen avoidance is still the main approach, new options like immunotherapy and biologics are showing promise.3

Recent findings emphasize that taking early, proactive action with advanced treatments can dramatically improve outcomes for patients, potentially changing the very course of this chronic skin condition.8,9

Traditionally, atopic eczema management has focused on treating symptoms as they arise, especially with topical creams for milder cases.8 However, a deeper understanding of the disease and the development of novel systemic treatments – medications that work throughout the body – reveal a powerful opportunity to intervene much earlier.8 This forward-thinking strategy moves beyond simply reacting to flare-ups; it aims to target the underlying immune imbalance and inflammation that drive eczema from its earliest stages.8

One of the most significant benefits of this early approach is its potential to halt the “atopic march”.9 This refers to the common progression where atopic eczema, often appearing first in infancy or childhood, is followed by other allergic conditions such as food allergies, allergic rhinitis, or asthma.9 By addressing the skin barrier dysfunction and immune system changes early on, we may be able to prevent or reduce the development of these related allergies.9 Studies suggest that allergic sensitization can occur through an impaired skin barrier, and early treatment of this dysfunction could serve as a preventive strategy for food allergy progression.9

Furthermore, early intervention is key to breaking the relentless “itch-scratch cycle”.8 Chronic itching, a hallmark of atopic eczema, not only causes immense discomfort but also leads to skin damage and secondary complications like infections. 8 By addressing the root causes of itching, patients can experience comprehensive relief, regain normalcy, and significantly improve their overall quality of life, sleep, and mental well-being by reducing anxiety, depression, and social isolation associated with the disease.8

This proactive strategy also offers the promise of long-term disease control and modification.8 By tackling inflammation before visible skin lesions fully develop, it can inhibit the escalation of inflammatory responses and disrupt the recurring cycles of flares and remissions.8  

“The paradigm shift towards early systemic intervention represents a pivotal moment in atopic eczema care,” says Dr. Koot. “It’s about empowering patients with strategies that offer not just immediate relief, but also the potential for sustained positive outcomes and a better quality of life by addressing the disease at its inception, rather than solely managing its symptoms after they become severe.”

Working together

“World Atopic Eczema Day 2025 is a call to action,” says Dr Koot. “Doctors need to see atopic eczema as a systemic disease that needs more than just symptom relief. Policymakers need to support early treatment, better access to specialist care, affordable medicines, and stronger investment in research and innovation. Families and patient groups play a key role in showing the true impact of atopic eczema and pushing for advanced, targeted therapies.”

The campaign also recognises the importance of community. Social media initiatives such as #AtopicEczemaJourney give patients and families a space to share their stories, connect with others and draw attention to the reality of living with atopic eczema.

“Progress is possible, but it requires commitment from everyone,” says Dr Koot. “Research shows that simple measures, such as protecting infant skin with frequent use of emollients and avoiding triggers, can drastically improve control of atopic eczema. Public health strategies, better access to care, early intervention and investment in new treatments all make a difference. At the same time, society needs to understand that atopic eczema is not only about rashes or itching. It is a systemic, lifelong condition that affects education, careers, relationships and quality of life.”

Categories : Dermatology Injury & TraumaTags :

“Skin in a Syringe” a Step Towards a New Way to Heal Burns

On By ModernMedia
Researchers in fields such as regenerative medicine and materials science have collaborated to develop a gel containing living cells that can be 3D-printed into a transplant. Photographer: Magnus Johansson

Finding a way to replicate the skin’s complicated dermis layer has long been a goal of healing burn wounds, as it would greatly reduce scarring and restore functionality. Researchers at Linköping University have developed a gel containing living cells that can be 3D-printed onto a transplant, which then sticks to the wound and creates a scaffold for the dermis to grow.

Large burns are often treated by transplanting a thin layer of the top part of the skin, the epidermis, which is basically composed of a single cell type. Transplanting only this part of the skin leads to severe scarring.

“Skin in a syringe”

Beneath the epidermis is the dermis, which has the blood vessels, nerves, hair follicles and other structures necessary for skin function and elasticity. However, transplanting also the dermis is rarely an option, as the procedure leaves a wound as large as the wound to be healed. The trick is to create new skin that does not become scar tissue but a functioning dermis.

“The dermis is so complicated that we can’t grow it in a lab. We don’t even know what all its components are. That’s why we, and many others, think that we could possibly transplant the building blocks and then let the body make the dermis itself,” says Johan Junker, researcher at the Swedish Center for Disaster Medicine and Traumatology and docent in plastic surgery at Linköping University, who led the study published in Advanced Healthcare Materials.

The most common cell type in the dermis, the connective tissue cell or fibroblast, is easy to remove from the body and grow in a lab. The connective tissue cell also has the advantage of being able to develop into more specialised cell types depending on what is needed. The researchers behind the study provide a scaffold by having the cells grow on tiny, porous beads of gelatine, a substance similar to skin collagen. But a liquid containing these beads poured on a wound will not stay there.

The researchers’ solution to the problem is mixing the gelatine beads with a gel consisting of another body-specific substance, hyaluronic acid. When the beads and gel are mixed, they are connected using what is known as click chemistry. The result is a gel that, somewhat simplified, can be called skin in a syringe.

“The gel has a special feature that means that it becomes liquid when exposed to light pressure. You can use a syringe to apply it to a wound, for example, and once applied it becomes gel-like again. This also makes it possible to 3D print the gel with the cells in it,” says Daniel Aili, professor of molecular physics at Linköping University, who led the study together with Johan Junker.

3D-printed transplant

In the current study, the researchers 3D-printed small pucks that were placed under the skin of mice. The results point to the potential of this technology to be used to grow the patient’s own cells from a minimal skin biopsy, which are then 3D-printed into a graft and applied to the wound.

“We see that the cells survive and it’s clear that they produce different substances that are needed to create new dermis. In addition, blood vessels are formed in the grafts, which is important for the tissue to survive in the body. We find this material very promising,” says Johan Junker.

Blood vessels are key to a variety of applications for engineered tissue-like materials. Scientists can grow cells in three-dimensional materials that can be used to build organoids. But there is a bottleneck as concerns these tissue models; they lack blood vessels to transport oxygen and nutrients to the cells. This means that there is a limit to how large the structures can get before the cells at the centre die from oxygen and nutrient deficiency.

Step towards labgrown blood vessels

The LiU researchers may be one step closer to solving the problem of blood vessel supply. In another article, also published in Advanced Healthcare Materials, the researchers describe a method for making threads from materials consisting of 98 per cent water, known as hydrogels.

“The hydrogel threads become quite elastic, so we can tie knots on them. We also show that they can be formed into mini-tubes, which we can pump fluid through or have blood vessel cells grow in,” says Daniel Aili.

The mini-tubes, or the perfusable channels as the researchers also call them, open up new possibilities for the development of blood vessels for eg, organoids.

Source: Linköping University